Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: A Study of Combination Therapies to Treat COVID-19 Infection

Eligibility criteria:
Inclusion Criteria:

          1. Signed informed consent, demonstrating that the subject understands the procedures
             required for the study and the purpose of the study

          2. Healthy, ambulant male or female subjects 18 years of age to 65 years of age

          3. Positive test for COVID-19 by RT-PCR at screening

          4. Subjects must agree to practice at least one highly effective method of birth control
             for the duration of the study. This includes condoms with spermicide, oral birth
             control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects
             not of reproductive potential will be exempt (e.g. post-menopausal, surgically
             sterilized)

          5. Subjects must agree they will do their best to attend the treatment facility daily for
             10 days

        Exclusion Criteria:

          1. Refusal to sign informed consent form

          2. Negative test for COVID-19 by RT-PCR at screening

          3. Severe disease symptomatically including pneumonia, respiratory distress, tachypnea,
             shortness of breath, temperature > 38 degrees; pleuritic pain, or frequent cough.

          4. Known drug allergy to any of the investigational medications

          5. Currently taking medication with known drug interactions with investigational
             medications (listed in appendix)

          6. Prescription or other antiviral medications

          7. Any comorbidities which constitute health risk for the subject

          8. Pregnant or lactating females;

          9. weight < 110lb;

         10. porphyria

         11. established retinal disease

         12. Inability to attend daily for 10 days

         13. Any contraindications for treatment with hydroxychloroquine

               1. Hypoglycemia

               2. Known G6PD deficiency

               3. Porphyria

               4. Anemia

               5. Neutropenia

               6. Alcoholism

               7. Myasthenia gravis

               8. Skeletal muscle disorders

               9. Maculopathy

              10. Changes in visual field

              11. Liver disease

              12. Psoriasis

              13. History of QT >500msec

              14. History of torsades de pointes

         14. Anemia from pyruvate kinase and G6PD deficiencies

         15. Abnormal EKG with QT prolongation acquired or from birth

         16. History of jaundice or high fevers prior to developing COVID-19

         17. Treatment with any of the medications listed in Appendix II

         18. Treatment with any anti-epileptic medication

         19. Treatment with any other drug not listed that affects the QT interval
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 65 Years

Eligibility (NLI label): Entailment